Mode
Text Size
Log in / Sign up
Phase 4 N=120 Randomized Double-blind Treatment

Transverse Abdominis Plane (TAP) Block After Cesarean Delivery

Postoperative Pain · Pregnancy · Obesity

Enrolled (actual)
120
Serious AEs
0.0%
Results posted
Dec 2021
Primary outcome: Primary: Morphine Equivalents 0-24 Hours (Mgs) — 54; 38; 32; 45 Morphine equivalents (mg) — p=.05

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
0.9% Normal Saline (Drug); 0.2% Ropivacaine (Drug); 0.5% Ropivacaine (Drug); 0.75% Ropivacaine (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Northwestern University
Primary completion
Jan 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Morphine Equivalents 0-24 Hours (Mgs)
54; 38; 32; 45 .05
SECONDARY
Morphine Equivalents 24-72 Hours (Mgs)
67; 60; 67; 67
SECONDARY
Morphine Equivalents Total (Mgs)
120; 96; 98; 112
SECONDARY
Time to First PCA Request
90; 118; 126; 83
SECONDARY
Pain Scores at Rest
3; 3; 2; 2; 3; 1
SECONDARY
Pain Scores With Movement
5; 3.5; 3.5; 4; 4; 2
SECONDARY
Pain Burden at Rest
129; 79; 79; 151
SECONDARY
Pain Burden With Movement
265; 202; 233; 327

Summary

Since there have been no published dose-response studies investigating the effective analgesic dose of ropivacaine for use in a TAP block for post-Cesarean delivery analgesia, the investigators propose a study primarily examining the effect on 24 hour post-Cesarean delivery opioid consumption of using either a placebo, 0.25% ropivacaine, 0.5% ropivacaine, or 0.75% ropivacaine for TAP blocks.

Eligibility Criteria

Inclusion Criteria

  • ASA II-III patient
  • > 18 years of age who is pregnant
  • presenting for a cesarean delivery via Pfannenstiel incision who is eligible to receive a spinal anesthetic with 0.75% bupivacaine and fentanyl and whose is not eligible to receive intrathecal morphine due to a BMI >40 kg/m2.

Exclusion Criteria

  • < 18 years of age
  • contraindication to placement of a spinal anesthetic
  • contraindication to use of non-steroidal anti-inflammatory drugs (NSAIDs)
  • patients receiving medical therapies considered to result in tolerance to opioids
  • patients with a history of established chronic pain, (e.g. chronic low back pain, fibromyalgia or headaches), defined as requiring regular medical follow-up with pain specialists, as well as recent use (within the year preceding pregnancy) of opioid analgesics as an outpatient
  • patients with a history of diabetes mellitus
  • patients undergoing a vertical midline skin incision
  • patients who are undergoing a cesarean delivery after a failed vaginal trial of labor
  • patients who had a prior epidural placed for labor analgesia during the same hospital encounter.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01170702). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search